Add this topic to your myFT Digest for news straight to your inbox
Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies
Agreement to limit the size of the NHS drugs bill under strain
US drugs maker also says low pricing of NHS purchases risks harming Britain’s push in life sciences
Groups say continuation of a scheme aimed at limiting NHS’s medicines bill will reduce or end their British operations
Makers of blockbuster drugs including Eli Lilly, AbbVie and AstraZeneca face new curbs
Competition and Markets Authority cuts £20mn from previous penalty after long legal battle
CEO of Asia’s largest pharma company warns recession risk, Ukraine war and Covid will hit healthcare spending
Move could boost global development of drugs to ease antimicrobial resistance
Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns
Executive says patients on other medications will not be able to take competing antiviral treatment
New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?
A successful split of the consumer and pharma divisions would, on paper, unlock value
Reforms included in Biden’s $1.75tn spending bill would see US government negotiate directly with drugmakers
Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people
Bill to allow US government to negotiate lower medicine prices for elderly people fails to advance
Health service to target use of Novartis drug inclisiran in bid to prevent cardiovascular disease in England
UK watchdog finds pharma groups ‘exploited a loophole’ to increase cost of pills by more than 2,000%
UK regulator penalises pharma company and buyout firms Cinven and Hg after NHS hit by ‘unfair’ rises
UK watchdog imposes £260m in penalties for increases in costs of hydrocortisone tablets
US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment
Cases of the deadly infection have soared among coronavirus patients in India and Nepal
Moves to ease market access for generic drugmakers are gaining momentum
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line
International Edition